BR112013002461A2 - método para produzir um composto, e, cristal de um composto - Google Patents

método para produzir um composto, e, cristal de um composto

Info

Publication number
BR112013002461A2
BR112013002461A2 BR112013002461A BR112013002461A BR112013002461A2 BR 112013002461 A2 BR112013002461 A2 BR 112013002461A2 BR 112013002461 A BR112013002461 A BR 112013002461A BR 112013002461 A BR112013002461 A BR 112013002461A BR 112013002461 A2 BR112013002461 A2 BR 112013002461A2
Authority
BR
Brazil
Prior art keywords
compound
lower alkyl
alkyl group
optionally substituted
group
Prior art date
Application number
BR112013002461A
Other languages
English (en)
Inventor
Diasuke Yamada
Fumiya Ikarashi
Kazuya Okamoto
Moriyasu Masui
Yukihito Sumino
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of BR112013002461A2 publication Critical patent/BR112013002461A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

método para produzir um composto, e, cristal de um composto. um processo para preparar um composto representado pela fórmula (y1) ou (y2) [ em que rx é um grupo carbociclil alquila inferior opcionalmente substituído, ou os semelhantes], usando um processo novo para preparar um derivado de píridona representao pela fórmula (x4) [em que r1d é hidrogênio, halogênio, ou os semelhantes; r2d é hidrogênio, um grupo alquila inferior, ou os semelhantes,o dito grupo alquila inferior sendo opcionalmente substitído com um ou mais selecionados do grupo substituinte f; r4d é um grupo alquila inferior ou os semelhantes, o dito grupo alquila inferior sendo opcionalmente substituído com um ou mais selecionados do grupo substituinte e; e r6d é um grupo alquila inferior ou os semelhantes, o dito grupo alquila inferior sendo opcionalmente substituído com um ou mais selecionados do grupo de substituinte e].
BR112013002461A 2010-08-05 2011-08-04 método para produzir um composto, e, cristal de um composto BR112013002461A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010175899 2010-08-05
JP2010277713 2010-12-14
PCT/JP2011/067832 WO2012018065A1 (ja) 2010-08-05 2011-08-04 Ｈｉｖインテグラーゼ阻害活性を有する化合物の製造方法

Publications (1)

Publication Number Publication Date
BR112013002461A2 true BR112013002461A2 (pt) 2016-05-24

Family

ID=45559561

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013002461A BR112013002461A2 (pt) 2010-08-05 2011-08-04 método para produzir um composto, e, cristal de um composto

Country Status (18)

Country Link
US (8) US20140011995A1 (pt)
EP (3) EP3456721B1 (pt)
JP (1) JP5636054B2 (pt)
CN (3) CN106083891B (pt)
BR (1) BR112013002461A2 (pt)
CY (1) CY1124582T1 (pt)
DK (1) DK3456721T3 (pt)
ES (3) ES2710609T3 (pt)
HR (1) HRP20210748T1 (pt)
HU (1) HUE054473T2 (pt)
LT (1) LT3456721T (pt)
PL (1) PL3456721T3 (pt)
PT (3) PT2602260T (pt)
RS (1) RS61796B1 (pt)
SG (1) SG187683A1 (pt)
SI (1) SI3456721T1 (pt)
TW (1) TWI510451B (pt)
WO (1) WO2012018065A1 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2320909B8 (en) 2008-07-25 2016-03-30 VIIV Healthcare Company Chemical compounds
MX2011006241A (es) 2008-12-11 2011-06-28 Shionogi & Co Sintesis de inhibidores de integrasa de vih de carbamoil-piridona e intermediarios.
ES2964383T3 (es) 2008-12-11 2024-04-05 Viiv Healthcare Co Procesos e intermedios para inhibidores de la integrasa del VIH de carbamoilpiridona
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
TWI582097B (zh) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
CN106083891B (zh) * 2010-08-05 2018-03-23 盐野义制药株式会社 具有hiv整合酶抑制活性的化合物的制造方法
KR102527797B1 (ko) 2012-12-21 2023-05-03 길리애드 사이언시즈, 인코포레이티드 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
NO2865735T3 (pt) 2013-07-12 2018-07-21
CA2916993C (en) 2013-07-12 2019-01-15 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EP3096763B1 (en) * 2014-01-21 2019-12-25 Laurus Labs Limited Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
CN105121409B (zh) * 2014-03-19 2017-05-24 杭州普晒医药科技有限公司 德罗格韦钠盐的晶型及其制备方法
NO2717902T3 (pt) 2014-06-20 2018-06-23
TWI744723B (zh) * 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
EP3229804B1 (en) * 2014-12-09 2020-05-06 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
WO2016092527A1 (en) * 2014-12-12 2016-06-16 Sun Pharmaceutical Industries Limited A process for the preparation of dolutegravir
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
CN104557686A (zh) * 2014-12-29 2015-04-29 徐俊烨 一种吡啶酮类化合物的合成方法
EP3045461A1 (en) * 2015-01-16 2016-07-20 LEK Pharmaceuticals d.d. Processes for preparing dolutegravir and analogues thereof
AU2016244035B2 (en) 2015-04-02 2018-11-01 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EP3394069B1 (en) * 2015-12-21 2019-05-22 Lupin Limited Process for the preparation of hiv integrase inhibitors
EP4299133A3 (en) * 2016-06-23 2024-03-13 VIIV Healthcare Company Compositions and methods for the delivery of therapeutics
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
WO2018229798A1 (en) * 2017-06-13 2018-12-20 Cipla Limited Process for the preparation of bictegravir and intermediate thereof
CA3078442A1 (en) 2017-10-06 2019-04-11 Shionogi & Co., Ltd. Stereoselective process for preparing substituted polycyclic pyridone derivatives
CN108101838B (zh) * 2017-12-18 2020-10-20 安徽唯诗杨信息科技有限公司 一种度鲁特韦中间体的合成方法及其有关物质检测方法
US11634431B2 (en) 2018-07-12 2023-04-25 Laurus Labs Limited Process for purification of protected polycyclic carbamoylpyridone derivatives
CN113226319B (zh) 2018-10-22 2023-04-11 内布拉斯加大学董事会 抗病毒前药及其纳米制剂
EP4122537A1 (en) 2019-03-22 2023-01-25 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
CN110128448A (zh) * 2019-05-22 2019-08-16 博诺康源(北京)药业科技有限公司 一种度鲁特韦原料及中间体中非对映异构体杂质的合成方法
CN110396099A (zh) * 2019-05-22 2019-11-01 博诺康源(北京)药业科技有限公司 一种度鲁特韦原料中非对映异构体杂质的合成方法
US20200398978A1 (en) 2019-06-20 2020-12-24 Bell Helicopter Textron Inc. Low-drag rotor blade extension
US11248005B2 (en) 2019-07-08 2022-02-15 Lupin Limited Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor
CN110698473B (zh) * 2019-10-08 2020-12-18 浙江大学 哌嗪酮并羟基吡啶酮-5-羧基类化合物及制备和应用
US11697652B2 (en) 2020-02-24 2023-07-11 Gilead Sciences, Inc. Tetracyclic compounds and uses thereof
CN111620891B (zh) * 2020-05-27 2023-07-14 上海启讯医药科技有限公司 一种多替拉韦关键中间体溶剂化物多晶型物及其制备方法和用途
EP4249077A1 (en) 2020-11-17 2023-09-27 Shionogi & Co., Ltd Novel acridinium salt and method for producing same
CN112480007B (zh) * 2020-12-08 2022-11-18 宿迁市科莱博生物化学有限公司 一种1，3-二甲基-1h-吡唑-4-羧酸的合成方法
WO2022159387A1 (en) 2021-01-19 2022-07-28 Gilead Sciences, Inc. Substituted pyridotriazine compounds and uses thereof
WO2023175386A2 (en) * 2021-10-08 2023-09-21 Laurus Labs Limited Processes for preparation of cabotegravir or its pharmaceutically acceptable salts thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769380A (en) 1983-04-29 1988-09-06 Merrell Dow Pharmaceuticals Inc. Cardiotonic 5-benzoyl-1,2-dihydro-2-oxo-3-pyridinecarboxylates
JP4436229B2 (ja) 2004-10-20 2010-03-24 株式会社沖データ 電子装置
EP1852434B1 (en) 2005-02-21 2011-07-13 Shionogi Co., Ltd. Bicyclic carbamoylpyridone derivative having hiv integrase inhibiting activity
WO2006116764A1 (en) * 2005-04-28 2006-11-02 Smithkline Beecham Corporation Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
UA96568C2 (en) * 2005-04-28 2011-11-25 Глаксосмиткляйн Ллк Polycyclic carbamoyl pyridone derivative as hiv-integrase inhibitor
JP5297105B2 (ja) 2008-07-04 2013-09-25 株式会社クボタ 乗用型田植機
JP4975690B2 (ja) 2008-07-07 2012-07-11 アルファフーズ株式会社 レトルト食品の製造方法
PT2320908E (pt) 2008-07-25 2014-03-06 Shionogi & Co Pró-fármacos de dolutegravir
WO2010011819A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
JP2010068253A (ja) 2008-09-10 2010-03-25 Sony Corp 暗号処理装置
JP2010068262A (ja) 2008-09-11 2010-03-25 New Japan Radio Co Ltd 電子ボリウム
JP2010067176A (ja) 2008-09-12 2010-03-25 Nec Corp 情報処理装置
MX2011006241A (es) 2008-12-11 2011-06-28 Shionogi & Co Sintesis de inhibidores de integrasa de vih de carbamoil-piridona e intermediarios.
EP2370419B1 (en) 2008-12-11 2017-09-27 Shionogi&Co., Ltd. Maltol ether processes and intermediates
ES2964383T3 (es) * 2008-12-11 2024-04-05 Viiv Healthcare Co Procesos e intermedios para inhibidores de la integrasa del VIH de carbamoilpiridona
TWI518084B (zh) * 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
TWI582097B (zh) * 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
CN106083891B (zh) * 2010-08-05 2018-03-23 盐野义制药株式会社 具有hiv整合酶抑制活性的化合物的制造方法

Also Published As

Publication number Publication date
EP2602260B1 (en) 2016-09-28
PT3127908T (pt) 2019-02-04
JPWO2012018065A1 (ja) 2013-10-03
TW201210990A (en) 2012-03-16
PL3456721T3 (pl) 2021-10-25
CN106083891B (zh) 2018-03-23
EP3456721A3 (en) 2019-03-27
US20150038702A1 (en) 2015-02-05
CN106046022B (zh) 2018-06-19
US10125147B2 (en) 2018-11-13
EP2602260A4 (en) 2014-01-01
US20180037591A1 (en) 2018-02-08
US20170240564A1 (en) 2017-08-24
CY1124582T1 (el) 2022-07-22
HRP20210748T1 (hr) 2021-06-25
DK3456721T3 (da) 2021-04-26
US20160229870A1 (en) 2016-08-11
US9969750B2 (en) 2018-05-15
CN106046022A (zh) 2016-10-26
EP3127908A2 (en) 2017-02-08
ES2608377T3 (es) 2017-04-10
SI3456721T1 (sl) 2021-05-31
US20180044351A1 (en) 2018-02-15
US9321789B2 (en) 2016-04-26
EP3456721A2 (en) 2019-03-20
RS61796B1 (sr) 2021-06-30
CN106083891A (zh) 2016-11-09
US9802959B2 (en) 2017-10-31
PT2602260T (pt) 2016-12-27
CN103154004B (zh) 2016-07-06
PT3456721T (pt) 2021-05-04
WO2012018065A1 (ja) 2012-02-09
CN103154004A (zh) 2013-06-12
ES2710609T3 (es) 2019-04-26
US9650394B2 (en) 2017-05-16
US20140011995A1 (en) 2014-01-09
HUE054473T2 (hu) 2021-09-28
ES2870006T3 (es) 2021-10-26
EP3127908A3 (en) 2017-02-15
EP3127908B1 (en) 2018-11-28
EP3456721B1 (en) 2021-02-24
US10125146B2 (en) 2018-11-13
TWI510451B (zh) 2015-12-01
EP2602260A1 (en) 2013-06-12
SG187683A1 (en) 2013-03-28
US20180037592A1 (en) 2018-02-08
US20180037593A1 (en) 2018-02-08
LT3456721T (lt) 2021-07-12
US10000508B2 (en) 2018-06-19
JP5636054B2 (ja) 2014-12-03

Similar Documents

Publication Publication Date Title
BR112013002461A2 (pt) método para produzir um composto, e, cristal de um composto
BR112014007674A2 (pt) método para produzir derivados de 4,4-diflúor-3,4-dihidroisoquinolina
MX2018016267A (es) Metodo para producir derivado de piridona policiclica sustituida y cristal del mismo.
EA201591503A1 (ru) Производные нафтиридина, полезные в качестве антагонистов альфа-v-бета-6 интегрина
BR112012020983A2 (pt) processo para a preparação de derivados isoxazolina
BR112012007085B8 (pt) processos para a preparação de derivados de benzil-benzeno substituídos com glicopiranosila
PE20130155A1 (es) Derivados de ariletinilo
EA201501122A1 (ru) Новые агонисты соматостатиновых рецепторов подтипа 4 (sstr4)
TN2015000261A1 (fr) Dérivés d'imidazopyridazine servant de modulateurs des recepteurs gabaa
UA109013C2 (en) INDOLISIN DERIVATIVES
PH12017500048A1 (en) Pyridone derivative having tetrahydropyranylmethyl group
MX2009008781A (es) Derivados de ciclohexano espirociclicos.
AU2012245971A8 (en) A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
BR112012032251A2 (pt) processo para a preparação de derivados da 2, 2-difluoroetilamina pela alquilação com 2,2 difluoroetil-1-haloetanos
MX2013000773A (es) Procedimiento de preparacion de derivados de amino-benzoil-benzofu rano.
BR112012030534A2 (pt) moduladores de receptores 5-ht e métodos de uso dos mesmos
MY157497A (en) Pyrazinooxazepine derivatives
MX347855B (es) Derivados de anilina, su preparación y su aplicación terapéutica.
BR112012027625A2 (pt) ligante para refratários monolíticos, refratário monolítico, e método de construção de refratários monolíticos
BR112012022823A8 (pt) Composto contendo anel de piridina
MX2013008256A (es) Derivados novedosos de tetrahidroquinolina.
MX2014004823A (es) Colorantes acidos de trisazo.
MX2013007462A (es) Procedimiento de preparacion de derivados de 3-alquilsulfinilbenzo ilo.
MX2013000294A (es) Intermedios y procedimiento de preparación de un inhibidor específico de la trombina.
BR112012017485A2 (pt) derivados de ácido carboxílico tendo um anel de oxazolpirimidina 2.5.7-substituído

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]